Novel Anticoagulant Use for Venous Thromboembolism: A 2013 Update.

03:28 EST 22nd December 2014 | BioPortfolio

Summary of "Novel Anticoagulant Use for Venous Thromboembolism: A 2013 Update."

OPINION
STATEMENT:
Many pharmacologic options are available for prevention and treatment of venous thromboembolism (VTE). The anticoagulant selected may vary according the individual patient situation such as the acute versus chronic setting, renal function and indication for either VTE prevention or treatment. Established methods of pharmacologic prophylaxis agents include heparinoids, injectable anti-Xa inhibition and vitamin K antagonists (VKA). The novel anticoagulants have recently been incorporated into orthopedic surgery prophylaxis pathways and can be used for VTE treatment. Chronic VTE management, however, has largely been managed with the use VKA. The advantages of VKA include low cost, familiarity with use, and established protocols to manage catastrophic bleeding. VKA use, however, poses hurdles including the fact that correct dosing can be empiric, the existence of multiple potential medication and dietary interactions, and the possiblity for complications when anticoagulation levels are not well monitored. In contrast, the novel anticoagulants offer ease of dosing, reliable pharmacokinetics and low risk of interactions with other medications or diet. Potential hazards of the novel anticoagulants include high costs, questionable therapeutic benefit in those with poor adherence, a reliance on renal clearance, lack of reliable reversibility in the event of catastrophic bleeding, as well as incomplete familiarity with use by the general practitioner. Although clinical trials demonstrate promise of greater applicability of use of these novel agents, hospital systems will need to simultaneously create a plan for appropriate management of the use of these agents, an anticoagulation stewardship program. As guidelines are adopted to prevent and manage VTE, an appreciation for this new level of complexity is essential.

Affiliation

Jefferson Vascular Center, Jefferson Medical College, Thomas Jefferson University Hospitals, 111 S. 11th Street, Suite 6270, Philadelphia, PA, 19107, USA, alejandro.perez@jefferson.edu.

Journal Details

This article was published in the following journal.

Name: Current treatment options in cardiovascular medicine
ISSN: 1092-8464
Pages:

Links

PubMed Articles [5542 Associated PubMed Articles listed on BioPortfolio]

Recurrence risk after limited duration of anticoagulant treatment for late second venous thromboembolism.

Introduction: Patients with a second venous thromboembolism generally receive anticoagulant treatment for indefinite duration, although it is known that the recurrence risk diminishes over time while ...

Clinical and Safety Outcomes Associated With Treatment of Acute Venous Thromboembolism: A Systematic Review and Meta-analysis.

Many anticoagulant strategies are available for the treatment of acute venous thromboembolism, yet little guidance exists regarding which drug is most effective and safe.

Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer.

Compared with patients without cancer, patients with cancer who receive anticoagulant treatment for venous thromboembolism (VTE) are more likely to develop recurrent VTE.

Sex Differences in Patients Receiving Anticoagulant Therapy for Venous Thromboembolism.

In patients with venous thromboembolism (VTE), the outcome during the course of anticoagulant therapy may differ according to the patient's sex. We used the RIETE (Registro Informatizado Enfermedad Tr...

Risk of venous thromboembolism in patients with idiopathic inflammatory myositis: a systematic review and meta-analysis.

We performed this meta-analysis to assess venous thromboembolism risk in patients with idiopathic inflammatory myositis (IIM). A comprehensive search was performed in MEDLINE, EMBASE and the Cochrane ...

Clinical Trials [615 Associated Clinical Trials listed on BioPortfolio]

Predicting Bleeding Risk on Anticoagulant Therapy for Venous Thromboembolism

The main objective of the study is to develop or validate a clinical prediction rule for major bleeding in patients on oral anticoagulant therapy who have been safely anticoagulated witho...

D-dimer to Select Patients With a First Unprovoked Venous Thromboembolism Who Can Have Anticoagulants Stopped at 3 Months

The purpose of this study is to determine if the risk of recurrent venous thromboembolism (VTE) after stopping therapy is low and acceptable in patients with a first unprovoked proximal de...

D-Dimer to Predict Recurrence in Patients With Multiple Episodes of Venous Thromboembolism

Optimal duration of oral anticoagulant therapy in patients with recurrent episodes of venous thromboembolism (VTE) is a matter of debate and recommendations are based on inadequate evidenc...

Prevention of Recurrence of Venous Thromboembolism in Patients With a History of Venous Thromboembolism

The study objective is to evaluate the efficacy and safety of oral YM150 for 52 weeks in patients with a history of venous thromboembolism.

Residual Vein Thrombosis Establishes the Optimal Duration of Oral Anticoagulants

ABSTRACT Background The optimal duration of oral anticoagulant treatment in patients with idiopathic venous thromboembolism is still uncertain . The present study addressed the possible ro...

Medical and Biotech [MESH] Definitions

Impaired venous blood flow or venous return (venous stasis), usually caused by inadequate venous valves. Venous insufficiency often occurs in the legs, and is associated with EDEMA and sometimes with VENOUS STASIS ULCERS at the ankle.

Obstruction of a vein or VEINS (embolism) by a blood clot (THROMBUS) in the blood stream.

Instruments that generate intermittent forces, uniformed or graduated, to facilitate the emptying of VEINS. These devices are used to reduce limb EDEMA and prevent venous THROMBOEMBOLISM, such as deep vein thrombosis in the legs.

An anticoagulant that acts by inhibiting the synthesis of vitamin K-dependent coagulation factors. Warfarin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, pulmonary embolism, and atrial fibrillation with embolization. It is also used as an adjunct in the prophylaxis of systemic embolism after myocardial infarction. Warfarin is also used as a rodenticide.

Rare vascular anomaly involving a communication between the intracranial and extracranial venous circulation via diploe, the central spongy layer of cranial bone. It is often characterized by dilated venous structures on the scalp due to abnormal drainage from the intracranial venous sinuses. Sinus pericranii can be congenital or traumatic in origin.

Search BioPortfolio:
Loading
Advertisement

Relevant Topic

Nephrology - kidney function
Latest News Clinical Trials Research Drugs Reports Corporate
Nephrology is a specialty of medicine and pediatrics that concerns itself with the study of normal kidney function, kidney problems, the treatment of kidney problems and renal replacement therapy (dialysis and kidney transplantation). Systemic conditions...

Advertisement